Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24832869 | 0.89 | BTK (0.37) | BTKJAK3FAAHPIK3CDPIK3R1 | |
| SCHEMBL24833200 | 0.77 | BTK (0.50) | BTKJAK3FAAH | |
| SCHEMBL16764385 | 0.76 | JAK3 (0.53) | BTKJAK3LCK | |
| SCHEMBL16764386 | 0.76 | JAK3 (0.53) | BTKJAK3LCK | |
| SCHEMBL24832840 | 0.76 | JAK3 (0.53) | BTKJAK3LCK | |
| SCHEMBL24834050 | 0.76 | JAK3 (0.53) | BTKJAK3PIK3CDPIK3R1LCK | |
| SCHEMBL24832842 | 0.76 | JAK3 (0.52) | BTKJAK3LCK | |
| SCHEMBL30165882 | 0.75 | LCK (0.40) | BTKJAK3LCKIRAK4 | |
| SCHEMBL24832843 | 0.75 | JAK3 (0.52) | BTKJAK3PIK3CDLCK | |
| SCHEMBL16764192 | 0.74 | JAK3 (0.53) | BTKJAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | BTK 1/4885JAK3 197/4885FAAH 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.